# MYBL1

## Overview
The MYBL1 gene encodes the MYB proto-oncogene like 1 protein, a transcription factor that plays a pivotal role in regulating gene expression across various biological processes. This protein is characterized by its DNA-binding domain, transactivation domain, and negative regulatory domain, which collectively facilitate its function in transcriptional regulation (Tang2012AMYB). MYBL1 is predominantly expressed in spermatocytes and breast epithelial cells, where it is crucial for processes such as spermatogenesis and breast development (Tang2012AMYB). The protein's interactions with coactivators like CBP and CREB are essential for its role in activating tissue-specific genes (FACCHINETTI1997Regulatory). MYBL1 is also implicated in various cancers, including salivary adenoid cystic carcinoma and triple-negative breast cancer, where alterations in the gene contribute to oncogenesis (Player2024Characterization; Mitani2016Novel). Additionally, MYBL1 is involved in endothelial cell function, particularly in regulating autophagy and lipid metabolism, which are vital for maintaining cellular homeostasis (Ding2024Downregulation).

## Structure
The MYBL1 protein is a transcription factor that contains several key domains, including a DNA-binding domain (DBD), a transactivation domain (TAD), and a negative regulatory domain (NRD) (Tang2012AMYB). The DBD is characterized by helix-turn-helix motifs, which are common in transcription factors and contribute to the protein's ability to bind specific DNA sequences. The TAD interacts with coactivators such as the KIX domain of CBP, enhancing promoter activity (Tang2012AMYB). The NRD is involved in regulating the protein's activity, and alterations in this domain can affect MYBL1's function (Mitani2016Novel).

MYBL1 undergoes alternative splicing, resulting in multiple isoforms with variations in their exon composition. For instance, the presence or absence of exon 15, which encodes part of the NRD, can lead to differences in the protein's regulatory capabilities (Player2024Characterization). Post-translational modifications such as phosphorylation, ubiquitination, and acetylation occur in regions like exon 15, influencing transactivation events (Player2024Characterization).

In certain cancers, MYBL1 can form fusion proteins, such as MYBL1-NFIB, which retain the DBD and TAD but lose the NRD, leading to altered transcriptional regulation (Mitani2016Novel). These structural changes can contribute to the protein's oncogenic potential.

## Function
The MYBL1 gene, also known as A-myb, encodes a transcription factor that plays a significant role in regulating gene expression during spermatogenesis and breast development. In healthy human cells, MYBL1 is predominantly expressed in spermatocytes and breast epithelial cells, where it acts as a coactivator to direct tissue-specific expression via the cAMP-responsive element (CRE) cis element (Tang2012AMYB). MYBL1 does not bind directly to DNA but stimulates gene expression through interactions with proteins such as CREB-binding protein (CBP) and CREB, facilitating the activation of testis-specific genes like Pgk2 and Pdha2 (Tang2012AMYB).

MYBL1 is crucial for male meiosis, with mutations in its transactivation domain leading to spermatogenic arrest at the pachytene stage (Tang2012AMYB). It is also involved in breast development, and its disruption can result in defective breast development and spermatogenic arrest in mice (Tang2012AMYB). In endothelial cells, MYBL1 regulates autophagy and lipid metabolism, promoting the fusion of autophagosomes and lysosomes, which is essential for reducing lipid accumulation and maintaining endothelial cell function (Ding2024Downregulation).

## Clinical Significance
Mutations and alterations in the MYBL1 gene have been implicated in several cancers. In salivary adenoid cystic carcinoma (ACC), MYBL1 rearrangements, including MYBL1-NFIB fusions, occur in cases lacking the common t(6;9) translocation. These rearrangements are mutually exclusive with MYB alterations and are involved in tumorigenesis by retaining DNA binding and transactivation domains (Mitani2016Novel). MYBL1 rearrangements in ACC are associated with high expression levels and poor patient outcomes, suggesting a significant role in the disease's progression (Gonda2016Adenoid).

In triple-negative breast cancer (TNBC), MYBL1 is frequently altered, with amplifications or high mRNA expression levels detected in 58% of patients. These alterations are often associated with other genes at the chromosome 8q loci, such as MYC, VCPIP1, and BOP1, indicating a potential role in TNBC pathogenesis (Player2024Characterization).

In pediatric low-grade gliomas, MYBL1 undergoes truncating rearrangements, leading to oncogenic transcripts that contribute to tumorigenesis. These alterations are particularly noted in specific histologic subtypes, such as DA2s, and are characterized by tandem duplication-truncation events (Ramkissoon2013Genomic). MYBL1's role in these gliomas highlights its involvement in cell-cycle regulation and tumor development.

## Interactions
MYBL1, also known as MYB proto-oncogene like 1, is a transcription factor that engages in various protein-protein and protein-DNA interactions, influencing gene expression and cellular processes. MYBL1 interacts with co-activator proteins such as CBP and p300, which are central regulators of gene transcription. These interactions are crucial for modulating transcriptional activity, as CBP and p300 enhance the transcriptional activation of target genes by MYBL1 (FACCHINETTI1997Regulatory). 

In the context of murine testis-specific gene expression, MYBL1 interacts with the CREB-binding protein (CBP) and CREB, forming a transcriptional initiation complex. This complex is essential for activating the Ldhc promoter through the CRE site, a common promoter element in primary spermatocytes. The interaction between MYBL1 and CREB is facilitated by the KIX domain of CBP, which binds to the transactivation domain of MYBL1 (Tang2012AMYB).

MYBL1 also plays a role in endothelial cells, where it interacts with PLEKHM1, a gene involved in autophagy. This interaction is significant in the context of atherosclerosis, as MYBL1 regulates autophagy-related processes by binding to the promoter of PLEKHM1, thereby influencing endothelial cell function and survival (Ding2024Downregulation).


## References


[1. (Player2024Characterization) Audrey Player, Sierra Cunningham, Deshai Philio, Renata Roy, Cydney Haynes, Christopher Dixon, Lataja Thirston, Fawaz Ibikunle, Taylor Allen Boswell, Ayah Alnakhalah, Juan Contreras, Myra Bell, Treveon McGuffery, Sahia Bryant, Chidinma Nganya, and Samuel Kanu. Characterization of mybl1 gene in triple-negative breast cancers and the genes’ relationship to alterations identified at the chromosome 8q loci. International Journal of Molecular Sciences, 25(5):2539, February 2024. URL: http://dx.doi.org/10.3390/ijms25052539, doi:10.3390/ijms25052539. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25052539)

[2. (Ding2024Downregulation) Shi-Ao Ding, Hao Liu, Rui Zheng, Yang Ge, Zheng Fu, Ju Mei, and Min Tang. Downregulation of mybl1 in endothelial cells contributes to atherosclerosis by repressing plekhm1-inducing autophagy. Cell Biology and Toxicology, May 2024. URL: http://dx.doi.org/10.1007/s10565-024-09873-6, doi:10.1007/s10565-024-09873-6. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10565-024-09873-6)

[3. (Tang2012AMYB) Huanghui Tang and Erwin Goldberg. A-myb (mybl1) stimulates murine testis-specific ldhc expression via the camp-responsive element (cre) site1. Biology of Reproduction, February 2012. URL: http://dx.doi.org/10.1095/biolreprod.111.095661, doi:10.1095/biolreprod.111.095661. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1095/biolreprod.111.095661)

[4. (Gonda2016Adenoid) Thomas J. Gonda and Robert G. Ramsay. Adenoid cystic carcinoma can be driven by myb or mybl1 rearrangements: new insights into myb and tumor biology. Cancer Discovery, 6(2):125–127, February 2016. URL: http://dx.doi.org/10.1158/2159-8290.cd-15-1470, doi:10.1158/2159-8290.cd-15-1470. This article has 22 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/2159-8290.cd-15-1470)

[5. (Ramkissoon2013Genomic) Lori A. Ramkissoon, Peleg M. Horowitz, Justin M. Craig, Shakti H. Ramkissoon, Benjamin E. Rich, Steven E. Schumacher, Aaron McKenna, Michael S. Lawrence, Guillaume Bergthold, Priscilla K. Brastianos, Barbara Tabak, Matthew D. Ducar, Paul Van Hummelen, Laura E. MacConaill, Tina Pouissant-Young, Yoon-Jae Cho, Hala Taha, Madeha Mahmoud, Daniel C. Bowers, Linda Margraf, Uri Tabori, Cynthia Hawkins, Roger J. Packer, D. Ashley Hill, Scott L. Pomeroy, Charles G. Eberhart, Ian F. Dunn, Liliana Goumnerova, Gad Getz, Jennifer A. Chan, Sandro Santagata, William C. Hahn, Charles D. Stiles, Azra H. Ligon, Mark W. Kieran, Rameen Beroukhim, and Keith L. Ligon. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factormybl1. Proceedings of the National Academy of Sciences, 110(20):8188–8193, April 2013. URL: http://dx.doi.org/10.1073/pnas.1300252110, doi:10.1073/pnas.1300252110. This article has 185 citations.](https://doi.org/10.1073/pnas.1300252110)

[6. (FACCHINETTI1997Regulatory) Valeria FACCHINETTI, Livio LOFFARELLI, Sabine SCHREEK, Michael OELGESCHLÄGER, Bernhard LÜSCHER, Martino INTRONA, and Josée GOLAY. Regulatory domains of the a-myb transcription factor and its interaction with the cbp/p300 adaptor molecules. Biochemical Journal, 324(3):729–736, June 1997. URL: http://dx.doi.org/10.1042/bj3240729, doi:10.1042/bj3240729. This article has 35 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj3240729)

[7. (Mitani2016Novel) Yoshitsugu Mitani, Bin Liu, Pulivarthi H. Rao, Vishnupriya J. Borra, Mark Zafereo, Randal S. Weber, Merrill Kies, Guillermina Lozano, P. Andrew Futreal, Carlos Caulin, and Adel K. El-Naggar. Novel mybl1 gene rearrangements with recurrent mybl1–nfib fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clinical Cancer Research, 22(3):725–733, January 2016. URL: http://dx.doi.org/10.1158/1078-0432.ccr-15-2867-t, doi:10.1158/1078-0432.ccr-15-2867-t. This article has 162 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-15-2867-t)